New in Vivo Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors
- 2 October 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (11) , 3715-3725
Abstract
Matrix metalloproteinases (MMPs) are emerging as pivotal fine tuners of cell function in tissue homeostasis and in various pathologies, in particular inflammation. In vivo monitoring of the activity of specific MMPs, therefore, provides high potential for assessing disease progression and tissue function, and manipulation of MMP activity in tissues and whole organisms may further provide a mode of controlling pathological processes. We describe here the synthesis of novel fluorinated and non-fluorinated analogues of a secondary sulfonamide-based lead structure, compound 2, and test their efficacy as in vivo inhibitors and tracers of the gelatinases, MMP-2 and MMP-9. Using a murine neuroinflammatory model, we show that compound 2 is a highly effective in vivo inhibitor of both MMP-2 and MMP-9 activity with little or no adverse effects even after long-term daily oral administration. A fluorescein-labelled derivative compound 17 shows direct binding to activated gelatinases surrounding inflammatory cuffs in the neuroinflammation model and to pancreatic β-cells in the islets of Langerhans, colocalizing with MMP-2 and MMP-9 activity as detected using in situ zymography techniques. These results demonstrate that compound 2 derivatives have potential as in vivo imaging tools and for future development for specific MMP-2 versus MMP-9 probes. Our chemical modifications mainly target the residues directed towards the S1’ and S2’ pockets and, thereby, provide new information on the structure-activity relationships of this inhibitor type.Keywords
Funding Information
- European Foundation for the Study of Diabetes
- Deutsche Forschungsgemeinschaft (EXE 1003)
This publication has 47 references indexed in Scilit:
- Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo EvaluationJournal of Medicinal Chemistry, 2013
- Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decadeCritical Reviews in Biochemistry and Molecular Biology, 2012
- Selective Water-Soluble Gelatinase Inhibitor ProdrugsJournal of Medicinal Chemistry, 2011
- From the X-ray Compact Structure to the Elongated Form of the Full-Length MMP-2 Enzyme in Solution: A Molecular Dynamics StudyJournal of the American Chemical Society, 2008
- Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitisJournal of Experimental Medicine, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding groupJBIC Journal of Biological Inorganic Chemistry, 2004
- Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulinThe FASEB Journal, 2003
- Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase‐inhibitorBritish Journal of Pharmacology, 2000
- A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinasesFEBS Letters, 1992